Canaccord analyst Richard Close raised the firm’s price target on HealthStream (HSTM) to $30 from $29 and keeps a Hold rating on the shares. The firm said they reported a respectable quarter, with revenue above and adj-EBITDA only slightly below Canaccord and consensus estimates.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HSTM:
- HealthStream Reports Strong 2024 Financial Performance
- HealthStream: Hold Rating Amid Mixed Financial Performance and Near-Term Challenges
- HealthStream’s Hold Rating: Balancing Revenue Growth with Cautious Outlook
- HealthStream’s Promising Growth and Stable Financial Performance Justify Buy Rating
- HealthStream Reports 2024 Financial Results and Growth